OGEN AMEX
Oragenics, Inc.
1W: +2.5%
1M: -1.2%
3M: -13.8%
YTD: -40.1%
1Y: -64.8%
3Y: -99.4%
5Y: -100.0%
$0.50
+0.02 (+4.15%)
Weekly Expected Move ±9.5%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships8
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-07-27
Earliest Filing
2026-01-22
Latest Filing
partner: 5
acquirer: 2
target: 1
Counterparties (Filed by OGEN)
8 relationshipsCompanies named in OGEN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Oragenics, Inc. | OGEN | acquirer | Company entering into ATM Sales Agreement amendment | 2026-01-22 | View |
| Oragenics, Inc. | OGEN | partner | Company issuing securities in the offering | 2024-06-26 | View |
| ORAGENICS, INC. | OGEN | target | Company issuing shares in an underwriting agreement | 2024-03-01 | View |
| THINKEQUITY LLC | — | acquirer | Representative of the several underwriters | 2024-03-01 | View |
| Inspirevax Inc. | — | partner | Oragenics entered an exclusive global license agreement with Inspirevax to develop an intranasal COVID-19 vaccine candid | 2023-03-01 | View |
| National Research Council of Canada | NRC | partner | Extended licensing and collaboration agreement for Omicron-specific intranasal vaccine development | 2021-12-20 | View |
| National Research Council of Canada | NRC | partner | Licensing agreement for antigen expression cell line technology to develop next-generation SARS-CoV-2 vaccines | 2021-07-27 | View |
| Biodextris | — | partner | Agreement for intranasal adjuvant to complement intramuscular administration options | 2021-07-27 | View |
Mentioned As Counterparty
1 mentionsOther companies that named OGEN in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-16 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-28 | Delisting Notice; Other Events; Exhibits | View | |
| 2026-07-06 | Material Agreement; Officer/Director Change; Shareholder Vote; Exhibits | Agreement | View |
| 2026-05-19 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-07 | Other Events; Exhibits | View | |
| 2026-04-13 | Other Events; Exhibits | View | |
| 2026-03-31 | Exhibits | View | |
| 2026-03-11 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-22 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-01-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-21 | Entry into Material Definitive Agreement; Notice of Delisting or Transfer; Regulation FD Disclosure; | Agreement | View |
| 2025-09-02 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-08-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-02 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders; Amend | Agreement | View |
| 2025-05-28 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-05-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-02 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-04-09 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR